Over-expression of CXCL2 is associated with poor prognosis in patients with ovarian cancer

Medicine (Baltimore). 2021 Jan 29;100(4):e24125. doi: 10.1097/MD.0000000000024125.

Abstract

Background: In the present study, we aimed to detect the expression of CXCL2 in epithelial ovarian cancer (OC) and explore its clinical significance.

Methods: TCGA (The Cancer Genome Atlas) database was adopted to assess the significance of CXCL2. Tissue microarray and immunohistochemical staining were used to detect the expression of CXCL2 in epithelial OC, and its correlation with clinicopathological features and prognosis was statistically analyzed.

Results: CXCL2 was highly expressed in epithelial OC tissues compared with the adjacent tissues. Such up-regulation of CXCL2 was significantly correlated with tumor differentiation (P = .001), tumor stage (P = .01), tumor location (unilateral or bilateral) (P = .003), and metastasis (P = .003). Kaplan-Meier and Cox proportional hazards regression analyses showed that high expression of CXCL2 was not an independent predictor of poor prognosis in epithelial OC.

Conclusions: Collectively, the high expression of CXCL2 might be related to the invasion and metastasis of epithelial OC.

MeSH terms

  • Age Factors
  • Biomarkers, Tumor
  • CA-125 Antigen / blood
  • Chemokine CXCL2 / biosynthesis*
  • Epithelium / metabolism
  • Female
  • Humans
  • Kaplan-Meier Estimate
  • Neoplasm Metastasis
  • Neoplasm Staging
  • Ovarian Neoplasms / pathology*
  • Prognosis
  • Proportional Hazards Models
  • Tissue Array Analysis

Substances

  • Biomarkers, Tumor
  • CA-125 Antigen
  • CXCL2 protein, human
  • Chemokine CXCL2